BridgeBio Pharma BBIO Interest Expense
Interest Expense at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's interest expense?
- BridgeBio Pharma (BBIO) reported interest expense of $12.94M in Q1 2026.
- How has BridgeBio Pharma's interest expense changed year-over-year?
- BridgeBio Pharma's interest expense decreased by 28.6% year-over-year, from $18.12M to $12.94M.
- What is the long-term trend for BridgeBio Pharma's interest expense?
- Over 4 years (2021 to 2025), BridgeBio Pharma's interest expense has grown at a 14.0% compound annual growth rate (CAGR), from $46.78M to $79.13M.
- What does interest expense mean?
- The cost of borrowing money, including interest payments on debt.
- How do you interpret interest expense?
- A decrease indicates reduced debt levels or improved credit terms, while an increase suggests higher leverage or rising interest rates.
- How does interest expense compare across companies?
- Varies based on the company's capital structure and reliance on debt financing versus equity.